Dublin, April 16, 2018 -- The "Global Stem Cell Partnering 2010-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.
The Global Stem Cell Partnering 2010-2018: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.
The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.
The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
Key benefits
- In-depth understanding of Stem Cell deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Stem Cell agreements with numerous real life case studies
- Detailed access to actual Stem Cell contracts entered into by leading biopharma companies
- Identify most active Stem Cell dealmakers since 2010
- Insight into terms included in a Stem Cell partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Stem Cell Partnering Terms and Agreements includes:
- Trends in Stem Cell dealmaking in the biopharma industry since 2010
- Analysis of Stem Cell deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Stem Cell deals
- Access to Stem Cell contract documents
- Leading Stem Cell deals by value since 2010
- Most active Stem Cell dealmakers since 2010
Available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Stem Cell dealmaking
Chapter 3 - Leading Stem Cell deals
Chapter 4 - Most active Stem Cell dealmakers
Chapter 5 - Stem Cell contracts dealmaking directory
Chapter 6 - Stem Cell dealmaking by technology type
Chapter 7 - Partnering resource center
For more information about this report visit https://www.researchandmarkets.com/research/bmcg8z/global_stem_cell?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Stem Cells


Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14%
OpenAI AI Agent Swarm Behind Hugging Face Hack
Jefferies Names AMEC Top China Semiconductor Equipment Pick
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns
Google Expands Gemini Enterprise With AI Tools for Legal Sector
Trump Administration Plans New Drug Pricing Deals With Biotech Firms
Honda, Nissan Eye Shared Vehicle Software Platform by 2029
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules
Amazon Secures 200 MW Wind Power Deals in Sweden
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation
Itochu Offers $1.56 Billion to Privatize Dentsu Soken
Mercer International Stock Surges 45% on C$20 Million Canada Funding 



